Cargando…
NovoTTF(™)-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL(™) system user study
BACKGROUND: Optune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields to the supratentorial brain. Patient therapy is personalized by c...
Autores principales: | Chaudhry, Aafia, Benson, Laura, Varshaver, Michael, Farber, Ori, Weinberg, Uri, Kirson, Eilon, Palti, Yoram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642621/ https://www.ncbi.nlm.nih.gov/pubmed/26558989 http://dx.doi.org/10.1186/s12957-015-0722-3 |
Ejemplares similares
-
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
por: Connelly, Jennifer, et al.
Publicado: (2016) -
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system
por: Turner, Scott G, et al.
Publicado: (2014) -
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
por: Swanson, Kenneth D., et al.
Publicado: (2016) -
Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
por: Wong, Eric T, et al.
Publicado: (2014) -
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
por: Wong, Eric T, et al.
Publicado: (2015)